Lisata Therapeutics (NASDAQ:LSTA) Trading 0.8% Higher – Still a Buy?

Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) shot up 0.8% during trading on Thursday . The stock traded as high as $2.68 and last traded at $2.64. 19,329 shares were traded during trading, a decline of 76% from the average session volume of 81,272 shares. The stock had previously closed at $2.62.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Stock Down 1.5 %

The stock has a market capitalization of $21.81 million, a P/E ratio of -1.04 and a beta of 1.14. The company has a 50 day moving average of $3.01 and a 200-day moving average of $2.99.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same quarter in the prior year, the company earned ($0.65) earnings per share. Equities analysts forecast that Lisata Therapeutics, Inc. will post -2.66 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.